[go: up one dir, main page]

MX2020001555A - Preparaciones terapéuticas de glicanos y métodos relacionados con estas. - Google Patents

Preparaciones terapéuticas de glicanos y métodos relacionados con estas.

Info

Publication number
MX2020001555A
MX2020001555A MX2020001555A MX2020001555A MX2020001555A MX 2020001555 A MX2020001555 A MX 2020001555A MX 2020001555 A MX2020001555 A MX 2020001555A MX 2020001555 A MX2020001555 A MX 2020001555A MX 2020001555 A MX2020001555 A MX 2020001555A
Authority
MX
Mexico
Prior art keywords
glycans
methods related
therapeutic preparations
methods
preparations
Prior art date
Application number
MX2020001555A
Other languages
English (en)
Other versions
MX381376B (es
Inventor
M Geremia John
Silverman Jared
J Yamanaka Yvonne
Milwid Jack
A Von Maltzahn Geoffrey
Original Assignee
Kaleido Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaleido Biosciences Inc filed Critical Kaleido Biosciences Inc
Publication of MX2020001555A publication Critical patent/MX2020001555A/es
Publication of MX381376B publication Critical patent/MX381376B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proporcionan preparaciones terapéuticas de glicanos, composiciones farmacéuticas y alimentos médicos de aquellas, que comprenden opcionalmente micronutrientes, polifenoles, prebióticos, probióticos u otros agentes, así como métodos para fabricarlas. También se proporcionan métodos para usar las preparaciones terapéuticas de glicanos, por ejemplo, para la modulación de la microbiota gastrointestinal humana y para tratar la disbiosis.
MX2020001555A 2015-01-26 2016-01-13 Preparaciones terapéuticas de glicanos y métodos relacionados con estas. MX381376B (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562108039P 2015-01-26 2015-01-26
US201562152017P 2015-04-23 2015-04-23
US201562152011P 2015-04-23 2015-04-23
US201562152007P 2015-04-23 2015-04-23
US201562152016P 2015-04-23 2015-04-23
US201562152005P 2015-04-23 2015-04-23
US201562216993P 2015-09-10 2015-09-10
US201562216995P 2015-09-10 2015-09-10
US201562217002P 2015-09-10 2015-09-10
US201562216997P 2015-09-10 2015-09-10
US201562238112P 2015-10-06 2015-10-06
US201562238110P 2015-10-06 2015-10-06
PCT/US2016/013305 WO2016122889A1 (en) 2015-01-26 2016-01-13 Glycan therapeutics and related methods thereof

Publications (2)

Publication Number Publication Date
MX2020001555A true MX2020001555A (es) 2021-04-09
MX381376B MX381376B (es) 2025-03-12

Family

ID=55349947

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009589A MX2017009589A (es) 2015-01-26 2016-01-13 Preparaciones terapeuticas de glicanos y metodos relacionados con estas.
MX2020001555A MX381376B (es) 2015-01-26 2016-01-13 Preparaciones terapéuticas de glicanos y métodos relacionados con estas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009589A MX2017009589A (es) 2015-01-26 2016-01-13 Preparaciones terapeuticas de glicanos y metodos relacionados con estas.

Country Status (23)

Country Link
US (6) US20170151268A1 (es)
EP (3) EP3862002A1 (es)
JP (3) JP2018502926A (es)
KR (1) KR20170122753A (es)
CN (1) CN107427528B (es)
AU (2) AU2016212030B2 (es)
BR (1) BR112017015614B1 (es)
CA (1) CA2973617A1 (es)
CL (1) CL2017001901A1 (es)
DK (2) DK3354282T3 (es)
EA (1) EA201791702A1 (es)
ES (2) ES2857557T3 (es)
IL (3) IL253195B (es)
LT (2) LT3354282T (es)
MX (2) MX2017009589A (es)
MY (1) MY188879A (es)
PH (1) PH12017501342B1 (es)
PL (2) PL3071235T3 (es)
PT (2) PT3354282T (es)
SG (2) SG10202103777UA (es)
SI (2) SI3354282T1 (es)
WO (1) WO2016122889A1 (es)
ZA (1) ZA201704735B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230113218A1 (en) * 2005-09-26 2023-04-13 Dsm Nutritional Products, Llc Glycan preparations for the treatment of infection
MY186844A (en) 2014-07-09 2021-08-25 Cadena Bio Inc Oligosaccharide compositions and methods for producing thereof
AU2016212030B2 (en) 2015-01-26 2021-06-17 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
US9492473B2 (en) * 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
EP3636077B1 (en) 2015-01-26 2022-11-16 Cadena Bio, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
CN107771083A (zh) 2015-04-23 2018-03-06 卡莱多生物科技有限公司 聚糖治疗剂和治疗方法
CN111888369A (zh) * 2015-08-25 2020-11-06 卡莱多生物科技有限公司 聚糖组合物及其用途
WO2018013871A1 (en) 2016-07-13 2018-01-18 Kaleido Biosciences, Inc. Glycan compositions and methods of use
US11959125B2 (en) * 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
EP3551194B1 (en) * 2016-12-06 2023-10-18 DSM Nutritional Products, LLC Glycan polymers and related methods thereof
AU2017379424B2 (en) 2016-12-23 2024-05-23 Murdoch Children's Research Institute Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants
AU2018250337B2 (en) * 2017-04-07 2024-02-15 Children's Hospital Medical Center Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
EP3630146A1 (en) * 2017-06-02 2020-04-08 Goodgut S.L. Grape skin for use in the treatment of dysbiosis
JP2020526541A (ja) 2017-07-13 2020-08-31 カレイド・バイオサイエンシズ・インコーポレイテッド グリカン組成物及び使用方法
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP6967404B2 (ja) * 2017-08-31 2021-11-17 雪印メグミルク株式会社 アッカーマンシア・ムシニフィラ増加促進用組成物
US11898184B2 (en) 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
US10894030B2 (en) 2017-09-13 2021-01-19 In Ingredients, Inc. Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
WO2019055513A1 (en) * 2017-09-13 2019-03-21 In Ingredients, Inc. INHIBITED PD-L1 EXPRESSION AND ENHANCED PD-1 EXPRESSION
WO2019064313A1 (en) * 2017-09-29 2019-04-04 Srh Nutrition Llp ANTIDIARRHETIC COMPOSITIONS BASED ON PLANTS
EP3704161A1 (en) 2017-11-03 2020-09-09 Kaleido Biosciences, Inc. Methods of producing glycan polymers
JP2021502338A (ja) * 2017-11-03 2021-01-28 カレイド・バイオサイエンシズ・インコーポレイテッド 感染の治療のためのグリカン調製物
EP3703705B1 (en) * 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
WO2019092896A1 (ja) * 2017-11-08 2019-05-16 アサヒグループホールディングス株式会社 アッカーマンシア・ムシニフィラ増殖材
CN112203668B (zh) * 2017-12-15 2024-02-06 绿十字生命健康有限公司 用于抑制和预防肾病发展的益生菌和包含其的用于抑制和预防肾病发展的组合物
WO2019136214A1 (en) * 2018-01-05 2019-07-11 California Institute Of Technology Probiotics, metabolites, and uses thereof
CN108125975A (zh) * 2018-01-29 2018-06-08 广东省农业科学院动物卫生研究所 野漆树苷在制备抗微小隐孢子虫药物中的应用
WO2019153334A1 (zh) * 2018-02-12 2019-08-15 天津天狮生物发展有限公司 一种调节人体肠道功能的复合益生元及其应用
WO2019162425A1 (en) * 2018-02-22 2019-08-29 Gnubiotics Sciences Sa New process of preparation of glycan composition & uses thereof
EP3530281A1 (en) * 2018-02-22 2019-08-28 Gnubiotics Sciences Sàrl New process of preparation of glycan compositions & uses thereof
CN108760900A (zh) * 2018-03-20 2018-11-06 华南理工大学 一种测定羧甲基纤维素钠取代度的顶空气相色谱法
WO2019205942A1 (zh) * 2018-04-27 2019-10-31 美益添生物医药(武汉)有限公司 一种提高肠道中scfa产生菌的复合制剂及制备方法与应用
CN108403930B (zh) * 2018-04-27 2021-08-20 美益添生物医药(武汉)有限公司 一种提高肠道中akk菌/致病菌比值的复合制剂及制备方法与应用
CN108567901B (zh) * 2018-04-27 2021-07-23 美益添生物医药(武汉)有限公司 一种提高肠道中scfa产生菌的复合制剂及制备方法与应用
JP7195067B2 (ja) * 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
US11026897B2 (en) * 2018-08-10 2021-06-08 Metagenics, Inc. Composition of curcumagalactomannoside and hops extract
US11925660B2 (en) 2018-08-10 2024-03-12 Simeon Investment, Inc. Treatment for obesity with superabsorbent materials
US11918602B2 (en) 2018-08-10 2024-03-05 Simeon Investment, Inc. Methods for reducing cholesterol with superabsorbent materials
US12285738B2 (en) 2018-08-10 2025-04-29 Simeon Investment, Inc. Modulation of glucose bioaccessibility with superabsorbent materials
US12410206B2 (en) 2018-08-21 2025-09-09 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods of use thereof for reducing ammonia levels
JP7223477B2 (ja) * 2018-10-10 2023-02-16 花王株式会社 Ｔｒｐｖ４活性抑制剤
IT201800009755A1 (it) * 2018-10-24 2020-04-24 Berardino Vaira Nuovi probiotici utili per eradicare l'infezione da helicobacter pylori
EP3877424A2 (en) 2018-11-08 2021-09-15 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof
KR102196047B1 (ko) * 2018-11-14 2020-12-29 건국대학교 글로컬산학협력단 메타중아황산염을 포함하는 사료 원료 보존용 조성물 및 이를 이용한 사료의 제조방법
TWI692777B (zh) * 2018-11-16 2020-05-01 長庚醫療財團法人高雄長庚紀念醫院 智能化急性腎損傷藥物警示系統
WO2020108812A1 (en) * 2018-11-26 2020-06-04 Purac Biochem B.V. Particulate food preservative composition
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
CN109633011A (zh) * 2018-12-29 2019-04-16 中山百灵生物技术有限公司 一种新的甘氨酸含量的检测方法
EP3917948A1 (en) 2019-01-31 2021-12-08 Gnubiotics Sciences SA Compositions derived from gastrointestinal tract mucins
US11788155B1 (en) * 2019-06-06 2023-10-17 University Of South Florida Lung microbiome isolation and cultivation
CN110115713A (zh) * 2019-06-20 2019-08-13 郑州康金瑞健康产业有限公司 一种止鼾液及其制备方法
AU2020315869A1 (en) * 2019-07-19 2022-01-20 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
US12473379B2 (en) * 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
US20240066072A1 (en) * 2019-10-03 2024-02-29 The Regents Of The University Of Michigan Clostrodioides difficile treatment
CN114585375A (zh) * 2019-10-21 2022-06-03 表飞鸣制药株式会社 尿毒素降低剂
KR102470108B1 (ko) * 2020-01-02 2022-11-23 삼육대학교산학협력단 부티리시모나스 속 균주를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물
KR102470116B1 (ko) * 2020-01-02 2022-11-23 삼육대학교산학협력단 부티리시모나스 속 균주를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
JP7796031B2 (ja) * 2020-03-13 2026-01-08 ディーエスエム アイピー アセッツ ビー．ブイ． 胃腸微生物代謝経路及び代謝物を調節する方法
CN116726055A (zh) * 2020-04-28 2023-09-12 香港中文大学 用于提高免疫力的组合物
US20210345634A1 (en) * 2020-05-07 2021-11-11 Christopher Burns Dissolving coffee beads
MX2022015060A (es) * 2020-05-29 2023-03-06 Cargill Inc Composición que comprende oligosacárido de glucosa y proceso para elaborar la misma y usarla.
EP4181910A4 (en) 2020-07-17 2024-06-05 DSM Nutritional Products, LLC OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE
CN111671911B (zh) * 2020-07-24 2021-08-10 刘艳 一种治疗盆底失驰缓型便秘的药物组合物及其制备方法
CN111999411B (zh) * 2020-09-01 2022-08-09 山东省农业科学院农业质量标准与检测技术研究所 果蔬中矢车菊素及3种花色苷的高效液相色谱检测方法
WO2022067131A1 (en) * 2020-09-25 2022-03-31 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use
JP2022092966A (ja) * 2020-12-11 2022-06-23 トヨタ自動車株式会社 ジペプチジルペプチダーゼｉｖ阻害剤、機能性表示食品
KR102294442B1 (ko) * 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 플란타럼 mg4555 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
KR102294437B1 (ko) * 2021-02-17 2021-08-27 주식회사 메디오젠 영유아 유래 유산균 락토바실러스 플란타럼 mg4553 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물
JP2024508944A (ja) 2021-03-08 2024-02-28 エキソポリマー インコーポレイテッド 局所用のバイオポリマー
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN113430242B (zh) * 2021-07-07 2022-02-18 北京浩鼎瑞生物科技有限公司 一种筛选对肠道微生态具有促进作用的提取物方法及将其用于靶向筛选益生菌的应用
EP4376813A4 (en) * 2021-07-26 2025-06-04 Ahmed, Suzanne DRUG DELIVERY PLATFORM FOR DELIVERING THERAPEUTIC AGENTS AND METHODS OF USING AND MAKING THE SAME
RU2770882C1 (ru) * 2021-08-23 2022-04-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Белгородский государственный аграрный университет имени В.Я. Горина" Способ получения хлорофиллсодержащего продукта в качестве пищевого красителя
EP4412620A4 (en) * 2021-10-04 2025-08-20 Dsm Nutritional Products Llc OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
CN113797183B (zh) * 2021-11-05 2022-08-19 安徽医科大学第一附属医院 五味子酚在制备防治霉酚酸所致腹泻药物中的应用
CN114166961B (zh) * 2021-11-17 2022-11-22 西南大学 一种测定柑桔汁产品中酚类化合物及其前处理的方法
CN114376939B (zh) * 2021-12-27 2023-08-25 广州丸美生物科技有限公司 一种多糖组合物及其制备方法与应用
EP4260864A1 (en) * 2022-04-13 2023-10-18 Bluestone Pharma GmbH Product comprising probiotics and isomaltulose and method of its production
WO2024192188A1 (en) * 2023-03-13 2024-09-19 University Of Connecticut Agents and methods for modulating clostridioides difficile infection
WO2025038777A2 (en) * 2023-08-16 2025-02-20 Bloom Science, Inc. Probiotics and methods to reduce appetite
GB202400064D0 (en) * 2024-01-03 2024-02-14 Maxstim Ltd Biostimulants
WO2025165725A1 (en) * 2024-02-02 2025-08-07 The Mosaic Company Trimethylamine n-oxide particles, compositions comprising the same, and methods of use thereof
US12144821B1 (en) 2024-02-02 2024-11-19 King Faisal University Selective 3-prenyl 5-methyl ether, 7-o-rhamnoside flavone for the treatment of hepatic cancer
CN117815443B (zh) * 2024-03-05 2024-05-17 江苏宝众宝达药业股份有限公司 一种保护透析血管通路的外用敷料及其制备方法
CN118340728B (zh) * 2024-06-18 2024-09-06 山东天宇生物科技有限公司 一种复合盐酸林可霉素可溶性粉及其制备方法
CN118845821B (zh) * 2024-09-23 2026-01-06 四川大学 昙花提取物在制备治疗/改善肠道疾病的药物中的应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2027904A (en) 1933-02-16 1936-01-14 Int Suiker En Alcohol Cie Inte Method of polymerizing monosaccharides
US2436967A (en) 1942-04-01 1948-03-02 Corn Prod Refining Co Polymerization of sugars
US2719179A (en) 1951-01-25 1955-09-27 Mora Peter Tibor Branched-chain carbohydrate polymers and their preparation
US3766165A (en) 1966-08-17 1973-10-16 Pfizer Polysaccharides and their preparation
US3876794A (en) 1972-12-20 1975-04-08 Pfizer Dietetic foods
US3973049A (en) 1974-03-14 1976-08-03 General Foods Corporation Method of mixing flavors and fixed composition comprising derivatized synthetic polysaccharides
US4965354A (en) 1988-02-26 1990-10-23 Taito Company, Ltd. Process for producing a condensed polysaccharide
US5667593A (en) 1989-01-26 1997-09-16 Cultor Ltd. Modified polydextrose and process therefor
TW203106B (es) 1991-07-18 1993-04-01 Textilma Ag
JPH06121693A (ja) 1992-08-25 1994-05-06 Akebono Brake Res & Dev Center Ltd 高重合度オリゴ糖の製造法
FR2697023B1 (fr) 1992-10-16 1994-12-30 Roquette Freres Polymère soluble hypocalorique du glucose et procédé de préparation de ce polymère .
US5843922A (en) 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US6475552B1 (en) 1997-03-19 2002-11-05 Danisco Finland Oy Polymerization of mono and disaccharides using low levels of polycarboxylic acids
KR100508765B1 (ko) 1997-03-19 2005-08-22 다니스코 쿨토 아메리카, 인코포레이티드 저수준의 무기산을 사용하는 모노- 및 디사카라이드의 중합 방법
JP3093194B2 (ja) * 1998-04-30 2000-10-03 韓国科学技術研究院 新規のペリヌス属菌株から分離した免疫増強活性多糖類物質及びその使用
US6251878B1 (en) * 1998-07-10 2001-06-26 Board Of Regents, The University Of Texas System Inhibition of UV-induced immune suppression and interleukin-10 production by cytoprotective tamarind oligosaccharides
DE19860376A1 (de) 1998-12-28 2000-07-06 Aventis Res & Tech Gmbh & Co Alpha-1,4 Glucanketten enthaltende Polysaccharide sowie Verfahren zu ihrer Herstellung
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CA2391966A1 (en) 1999-11-24 2001-05-31 Massachusetts Institute Of Technology Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries
US7608291B2 (en) 2000-03-10 2009-10-27 Mars, Inc. Treatment of infection in animals
DK1355542T3 (da) 2000-12-27 2007-06-11 Nutricia Nv Næringssammensætning med sundhedsfremmende virkning, som indeholder oligosaccharider
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
NZ515869A (en) 2001-11-30 2003-09-26 Med Chem Ingredients Ltd Compositions and methods for animal treatment comprising gluco- and isomalto- oligosaccharides
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
BR0311645A (pt) 2002-06-07 2005-02-22 Dzucker Ag Mannheim Ochsenfurt Isomalte de galactosila - procedimento para sua produção e emprego
DK1531832T3 (da) 2002-06-28 2009-07-27 Glykos Finland Oy Terapeutiske sammensætninger til anvendelse ved profylakse eller behandling af diarré
MXPA05000872A (es) 2002-07-23 2005-04-28 Neose Technologies Inc Sintesis de glicoproteinas utilizando glicosiltransferasas bacterianas.
US7268221B2 (en) 2002-08-23 2007-09-11 E.I. Du Pont De Nemours And Company Alpha(1,6)-linked glucose oligosaccharide hydrolyzing enzyme polynucleotides and polypeptides and methods of use thereof
US20040052915A1 (en) 2002-09-13 2004-03-18 Carlson Ting L. Use of low glycemic index sweeteners in food and beverage compositions
FR2844453B1 (fr) * 2002-09-13 2006-05-19 Agronomique Inst Nat Rech Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
FI20021772A7 (fi) 2002-10-04 2004-04-05 Biotie Therapies Oyj Uudet hiilihydraattikoostumukset ja menetelmä niiden valmistamiseksi
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7291607B2 (en) * 2003-05-20 2007-11-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Isomaltooligosaccharides from Leuconostoc as neutraceuticals
DK1644482T4 (da) 2003-06-30 2014-12-15 Clasado Inc Hidtil ukendt galactooligosaccharidpræparat og fremstillingen deraf
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
FR2874825B1 (fr) * 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US20060093592A1 (en) 2004-10-04 2006-05-04 Nutracea Synbiotics
DE102004058811A1 (de) 2004-12-07 2006-06-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Zuckeralkoholen
WO2007010084A2 (en) 2005-07-15 2007-01-25 Johannes Savolainen Immunostimulatory oligo- and polysaccharides and uses thereof
EP1916908A1 (en) 2005-07-27 2008-05-07 Cantabria Group LCC Phosphorylated glucomannane polysaccharides containing 1-6 and 1-2 linkages increase weight gain in poultry
US20070048432A1 (en) 2005-08-25 2007-03-01 Archer-Daniels-Midland Company Use of dextrin in animal feeds
DK1940243T3 (da) 2005-10-24 2011-11-14 Nestec Sa Kostfiberformulering og fremgangsmåde til indgivelse
US8057840B2 (en) 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
US8993039B2 (en) 2006-01-25 2015-03-31 Tate & Lyle Ingredients Americas Llc Fiber-containing carbohydrate composition
US7915235B2 (en) * 2006-03-20 2011-03-29 Brian Dieckgraefe High affinity ligands bind to clostridium difficile toxin A
WO2007117175A1 (en) 2006-04-10 2007-10-18 Avva Pharmaceuticals Ag Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders
EP1887017A1 (en) 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
FI20065593A7 (fi) 2006-09-26 2008-03-27 Valio Oy Menetelmä galakto-oligosakkarideja sisältävien tuotteiden valmistamiseksi ja niiden käyttö
US20130216693A1 (en) 2007-01-24 2013-08-22 Tate & Lyle Ingredients Americas Llc Fiber-containing carbohydrate composition
ES2304223B2 (es) 2007-03-08 2009-05-01 Universidad De Sevilla Nuevos caramelos con elevado contenido en oligosacaridos prebioticos, procedimiento de preparacion y utilizacion.
EP3115452B1 (en) * 2007-04-26 2019-10-16 Hayashibara Co., Ltd. Branched alpha-glucan, alpha-glucosyltransferase which forms glucan, their preparation and uses
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008156354A1 (en) 2007-06-21 2008-12-24 N.V. Nutricia Modulation of intestinal flora of hiv patients
US20110034407A1 (en) * 2007-12-21 2011-02-10 N. V. Nutricia Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota
WO2009152089A2 (en) 2008-06-09 2009-12-17 Temple-Inland Prebiotic composition and methods of making and using the same
ES2416086T3 (es) 2008-12-10 2013-07-30 Katholieke Universiteit Leuven Alimento que contiene arabinoxilano y oligosacáridos
WO2010105207A1 (en) 2009-03-13 2010-09-16 The Regents Of The University Of California Prebiotic oligosaccharides
AU2010245761B2 (en) 2009-05-07 2014-10-02 Tate & Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
AU2009347008B2 (en) 2009-05-27 2013-08-15 Clasado Limited Method of preventing diarrhoea
DK3932410T3 (da) 2009-07-15 2024-09-23 Nutricia Nv Blanding af ikke-fordøjelige oligosaccharider til stimulering af immunsystemet
US8691792B2 (en) 2009-08-05 2014-04-08 Nestec Sa Methods and compositions for improving gastrointetinal health
CA2791418C (en) * 2010-03-10 2016-07-05 Inovobiologic, Inc. Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
EP2401925B1 (fr) 2010-06-29 2014-05-07 Rosebud AG Produit prebiotique et procede de fabrication
US20140187474A1 (en) 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
ES2997366T3 (en) 2011-02-28 2025-02-17 Dsm Nutritional Products Llc Polymeric acid catalysts and uses thereof
US9234225B2 (en) 2011-05-13 2016-01-12 Glycom A/S Method for generating human milk oligosaccharides (HMOs) or precursors thereof
US20140328997A1 (en) 2011-09-08 2014-11-06 Rutgers, The State University Of New Jersey Production of Enriched Products
GB2511993B (en) 2011-11-30 2019-09-18 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
FR2987360B1 (fr) 2012-02-28 2014-03-28 Roquette Freres Maltodextrines hyperbranchees hypo-glycemiantes
EP2666788A1 (en) 2012-05-21 2013-11-27 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Glucan fibre
EP2888043A4 (en) 2012-08-24 2016-05-04 Midori Usa Inc POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTIONING LIGNIN-CONTAINING SUBSTANCES USING SUCH CATALYSTS
US20150202607A1 (en) 2012-08-24 2015-07-23 Midori Renewables, Inc. Polymeric and solid-supported catalysts, and methods of digesting cellulosic materials using such catalysts
WO2014031956A1 (en) 2012-08-24 2014-02-27 Midori Renewables, Inc. Polymeric and solid-supported catalysts, and methods of digesting cellulosic materials using such catalysts
US9238845B2 (en) 2012-08-24 2016-01-19 Midori Usa, Inc. Methods of producing sugars from biomass feedstocks
EP2769726B1 (en) 2013-02-21 2018-10-31 Jennewein Biotechnologie GmbH Synthetic or recombinant fucosylated Oligosaccarides for use in the treatment of infections
EA201591749A1 (ru) 2013-03-14 2016-04-29 МАЙДОРИ ЮЭсЭй, ИНК. Катализаторы на основе полимерных ионных солей и способы их получения
WO2014145276A1 (en) 2013-03-15 2014-09-18 Cargill, Incorporated Carbohydrate compositions
US20170216328A1 (en) 2014-04-04 2017-08-03 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
MY186844A (en) 2014-07-09 2021-08-25 Cadena Bio Inc Oligosaccharide compositions and methods for producing thereof
US20180000146A1 (en) 2015-01-26 2018-01-04 Midori Usa, Inc. Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof
EP3636077B1 (en) 2015-01-26 2022-11-16 Cadena Bio, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
US9492473B2 (en) 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
AU2016212030B2 (en) * 2015-01-26 2021-06-17 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
JP2018504142A (ja) 2015-01-26 2018-02-15 カデナ・バイオ・インコーポレイテッド 食物成分として使用するためのオリゴ糖組成物及びその生成方法
CN107771083A (zh) 2015-04-23 2018-03-06 卡莱多生物科技有限公司 聚糖治疗剂和治疗方法
EP3285778A2 (en) 2015-04-23 2018-02-28 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
WO2017083520A1 (en) 2015-11-13 2017-05-18 Cadena Bio, Inc. Animal therapeutic and feed compositions and methods of use
US11484547B2 (en) * 2018-01-08 2022-11-01 Performance Labs PTE. LTD. Compositions and methods for cholesterol, glucose and microbiome control

Also Published As

Publication number Publication date
EP3862002A1 (en) 2021-08-11
US20170151268A1 (en) 2017-06-01
EP3071235B1 (en) 2017-12-13
US10314853B2 (en) 2019-06-11
EA201791702A1 (ru) 2018-04-30
DK3354282T3 (da) 2021-03-08
EP3354282A1 (en) 2018-08-01
JP2021063079A (ja) 2021-04-22
ZA201704735B (en) 2019-02-27
AU2021203605A1 (en) 2021-07-01
US9757403B2 (en) 2017-09-12
PL3354282T3 (pl) 2021-07-05
JP2018502926A (ja) 2018-02-01
SI3354282T1 (sl) 2021-07-30
PL3071235T3 (pl) 2018-05-30
PH12017501342A1 (en) 2017-12-18
LT3071235T (lt) 2018-04-25
KR20170122753A (ko) 2017-11-06
JP7675309B2 (ja) 2025-05-13
CA2973617A1 (en) 2016-08-04
BR112017015614A2 (en) 2018-04-10
IL253195B (en) 2021-08-31
AU2016212030B2 (en) 2021-06-17
PT3354282T (pt) 2021-03-18
IL277342A (en) 2020-10-29
SG11201706033XA (en) 2017-08-30
CN107427528B (zh) 2022-09-23
MX381376B (es) 2025-03-12
BR112017015614B1 (pt) 2023-05-09
US10702542B2 (en) 2020-07-07
LT3354282T (lt) 2021-04-12
MX2017009589A (es) 2018-06-20
PH12017501342B1 (en) 2022-11-16
SG10202103777UA (en) 2021-05-28
US20200093851A1 (en) 2020-03-26
DK3071235T3 (en) 2018-02-19
EP3354282B1 (en) 2020-12-30
IL285179A (en) 2021-08-31
IL277342B (en) 2022-02-01
JP2023022175A (ja) 2023-02-14
US20170151269A1 (en) 2017-06-01
MY188879A (en) 2022-01-12
US20180147222A1 (en) 2018-05-31
SI3071235T1 (en) 2018-04-30
EP3071235A1 (en) 2016-09-28
ES2659648T3 (es) 2018-03-16
PT3071235T (pt) 2018-02-21
WO2016122889A1 (en) 2016-08-04
US10881676B2 (en) 2021-01-05
AU2016212030A1 (en) 2017-07-20
US20210113596A1 (en) 2021-04-22
ES2857557T3 (es) 2021-09-29
CL2017001901A1 (es) 2018-07-06
US11229660B2 (en) 2022-01-25
CN107427528A (zh) 2017-12-01
US20200093845A1 (en) 2020-03-26
IL253195A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2016172657A3 (en) Glycan therapeutics and methods of treatment
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX378273B (es) Compuestos activos hacia bromodominios.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
IL274123A (en) Co-crystals, their pharmaceutical preparations and treatment methods involving them
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
EP4331622A3 (en) Integrin binding peptides and uses thereof
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2019005821A (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas.
EP3509614A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LAFORA DISEASE
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
EP4548979A3 (en) Enhanced delivery of drugs to the brain
EP3716975A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MX371343B (es) Moduladores del receptor x hepatico (lxr).
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3131545C0 (en) USE OF ENOXIMONE FOR THE TREATMENT OF TOPICAL CONDITIONS ASSOCIATED WITH THE IMMUNE SYSTEM, IN PHARMACEUTICAL COMPOSITIONS AS WELL AS IN PHARMACEUTICAL PREPARATIONS
HK40036468A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same